Boots in the U.S.
This article was originally published in The Tan Sheet
Executive Summary
Firm will devote an additional $171 mil. (€1=$1.42) to support its three "core" brands - Clearasil, Stepsils medicated lozenges and Nuraphen analgesics - over the next four years. Increased support is part of Boots' effort to boost profit from the $84.9 mil. earned in 2001 to $142.5 mil. by 2005; the additional monies will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a "contemporary" perspective on acne. Four new Clearasil products also are slated to debut stateside later this year, firm notes. Boots acquired Clearasil from P&G in 2000 (1"The Tan Sheet" Oct. 23, 2000, p. 7)...
You may also be interested in...
P&G Divests Clearasil, Boots Healthcare Gains Access To U.S. Market
Boots Healthcare International's acquisition of the Clearasil acne prevention and treatment brand could be a springboard for creating an OTC marketing presence in the U.S.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.